A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities
Youzhi Xu(Tianjin University), Yinglan Zhao(Sichuan University), Wen Peng(Jiangsu Cancer Hospital), Guo‐Bo Li(Second Military Medical University), Luoting Yu(Sichuan University), Shengyong Yang(Sichuan University), Yan Li(Essen University Hospital), Peng Yang(Shihezi University), Nana Meng(Jiangsu University), Chunting Wang(National Sun Yat-sen University), Wenjie Lu(Anhui Medical University), Manli Li(Sichuan University), Siying Wang(Shanxi Province Hospital of Traditional Chinese Medicine), Lixin Kan(Sichuan University), Hongjun Lin(Institute of Bioinformatics)
Cited by 5
Related Papers
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.7k
Targeting cellular metabolism to improve cancer therapeutics
|Cell Death and Disease|2013|1k
Tumor biomarkers for diagnosis, prognosis and targeted therapy
|Signal Transduction and Targeted Therapy|2024|600
SARS-CoV-2 M <sup>pro</sup> inhibitors with antiviral activity in a transgenic mouse model
|Science|2021|449
Novel Small Organic Molecules for a Highly Enantioselective Direct Aldol Reaction
|Journal of the American Chemical Society|2003|429